T1	duration 496 533	October 1, 1985, to December 31, 1990
T2	eligibility 536 564	patients with localized DCIS
T3	control 595 605	lumpectomy
T4	control 641 676	lumpectomy followed by radiotherapy
T5	control-participants 620 623	403
T6	intervention-participants 687 690	410
T7	duration 775 805	May 9, 1991, to April 13, 1994
T8	control 855 867	LRT+ placebo
T9	control-participants 872 875	900
T10	intervention 880 895	LRT + tamoxifen
T11	intervention-participants 912 915	899
T12	outcome-Measure 937 954	I-IBTR, DCIS-IBTR
T13	outcome-Measure 956 990	contralateral breast cancers (CBC)
T14	outcome-Measure 992 1035	overall and breast cancer-specific survival
T15	outcome-Measure 1041 1062	survival after I-IBTR
T16	No-of-participants 1120 1123	813
T17	No-of-participants 1173 1177	1799
T18	outcome 1196 1207	IBTR events
T20	intervention-value 1264 1267	52%
T21	outcome 1427 1433	I-IBTR
T19	outcome 1254 1260	I-IBTR
T22	intervention-value 1437 1440	32%
T23	outcome 1543 1581	15-year cumulative incidence of I-IBTR
T24	control-value 1586 1591	19.4%
T25	intervention-value 1600 1604	8.9%
T26	control-value 1621 1626	10.0%
T27	intervention-value 1657 1661	8.5%
T28	outcome 1681 1745	15-year cumulative incidence of all contralateral breast cancers
T29	control-value 1750 1755	10.3%
T30	intervention-value 1764 1769	10.2%
T31	control-value 1786 1791	10.8%
T32	intervention-value 1822 1826	7.3%
T33	outcome 1879 1893	mortality risk
T34	outcome 2002 2008	deaths
T35	outcome 2105 2156	15-year cumulative incidence of breast cancer death
T36	control-value 2161 2165	3.1%
T37	intervention-value 2174 2178	4.7%
T38	control-value 2195 2199	2.7%
T39	intervention-value 2230 2234	2.3%
